Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study
Arthritis & Rheumatology · 2025
DOI: 10.1002/art.42997 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Alan Kivitz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Altoona Center for Clinical Research, Duncansville, Pennsylvania. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Antibodies, Monoclonal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Objective
The aim of this study was to evaluate the efficacy and safety of intravenous (IV) secukinumab in patients with active psoriatic arthritis (PsA).
Methods
INVIGORATE‐2 (NCT04209205) was a randomized, placebo‐controlled, phase 3 trial. Patients with active PsA were randomized 1:1 to receive IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every four weeks [q4w]) or placebo. At week 16, patients randomized to placebo were switched to IV secukinumab (3 mg/kg q4w), and patients who received IV secukinumab continued treatment through week 52. The primary efficacy endpoint was achievement of 50% improvement in American College of Rheumatology response criteria (ACR50) at week 16. Efficacy and safety were evaluated through weeks 52 and 60, respectively.
Results
Among 191 patients randomized to IV secukinumab and 190 to placebo/IV secukinumab, 177 (92.7%) and 170 (89.5%) completed the entire study period, respectively. A significantly higher proportion of patients who received IV secukinumab versus placebo achieved ACR50 at week 16 (31.4% vs 6.3%; adjusted P < 0.0001). All secondary efficacy endpoints were met at week 16 (all adjusted P < 0.05 using the predefined hypothesis‐testing hierarchy). Patients who switched from placebo to secukinumab at week 16 showed rapid improvements in ACR50 rates; by week 52, both treatment arms experienced similar improvements in efficacy outcomes. No new or unexpected safety signals were observed with receiving IV secukinumab. One death was reported in the placebo group before week 16.
Conclusion
IV secukinumab led to rapid and sustained improvements in clinical measures of PsA, and the safety profile was consistent with that of secukinumab administered subcutaneously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Altoona Center for Clinical Research, Duncansville, Pennsylvania.
- Institute of Rheumatology and Charles University in Prague, Prague, Czech Republic.
- Arthritis Center of Nebraska, Lincoln.
- Sharp Community Medical Group, La Mesa, California.
- SouthWest Arthritis Research Group, Mesquite, Texas.
- Highlands Advanced Rheumatology and Arthritis Center, Avon Park, Florida.
ORCID-Profile: Alan Kivitz
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Kivitz, A., Sedova, L., Churchill, M., Kotha, R., Singhal, A., Torres, A., Valenzuela, G., Whelan, S., Dumortier, T., Zhu, X., Martin, R., & Pricop, L. (2025). Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.42997
Vancouver
Kivitz A, Sedova L, Churchill M, Kotha R, Singhal A, Torres A, et al. Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study. Arthritis & Rheumatology. 2025. doi:10.1002/art.42997
BibTeX
@article{Kivitz2025,
author = {Kivitz, Alan and Sedova, Liliana and Churchill, Melvin and Kotha, Roshan and Singhal, Atul and Torres, Alexander and Valenzuela, Guillermo and Whelan, Sarah and Dumortier, Thomas and Zhu, Xuan and Martin, Ruvie and Pricop, Luminita},
title = {Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study},
journal = {Arthritis & Rheumatology},
year = {2025},
doi = {10.1002/art.42997}
}
EUVIMED